Clearwater Analytics
CWAN
$24.56
+0.04%
Clearwater Analytics Holdings, Inc. is a technology company providing a comprehensive software-as-a-service (SaaS) platform for investment portfolio accounting, reporting, and analytics, primarily serving institutional clients like insurance companies, asset managers, and hedge funds. The company has historically been a leader in back-office investment accounting but has expanded its platform through acquisitions to include front and middle-office capabilities, aiming to become a unified platform for the entire investment lifecycle. The current investor narrative is dominated by the market's assessment of its recent strategic acquisitions, such as Enfusion, and the subsequent integration risks and growth potential, as evidenced by a series of analyst downgrades in early 2026 shifting from 'Buy' or 'Outperform' to 'Neutral' or 'Hold' ratings.…
CWAN
Clearwater Analytics
$24.56
Related headlines
Investment Opinion: Should I buy CWAN Today?
Rating & Thesis: Hold. CWAN is a promising but unproven growth story in transition, currently burdened by integration risks and a loss of analyst conviction, making it prudent to wait for clearer signs of execution before committing new capital. The absence of a consensus price target underscores the high uncertainty.
Supporting Evidence: The stock trades at a demanding 8.95x trailing sales, though this is a significant de-rating from historical peaks. The forward P/E of 28.03x is more reasonable but hinges entirely on achieving the $1.21 EPS estimate. Revenue growth is explosive at 72% YoY, and gross margins are strong at 67%. Positive free cash flow of $164M TTM is a critical supportive data point. However, these strengths are counterbalanced by a net margin of -5.41% and the recent wave of analyst downgrades.
Risks & Conditions: The two biggest risks are integration execution failure and a subsequent earnings miss. This Hold rating would upgrade to Buy if the company demonstrates sustained quarterly net profitability and provides guidance that confirms the $1.21 EPS target is achievable. It would downgrade to Sell if revenue growth decelerates sharply post-acquisition or if operating margins deteriorate further. Based on the current data, the stock appears fairly valued to slightly overvalued, pricing in significant future success that is not yet evident in the bottom line.
Sign up to view all
CWAN 12-Month Price Forecast
The outlook for CWAN is balanced with a slight skew to the downside in the near term. The base case (55% probability) of muddling through integration is most likely, leading to sideways trading. The bull case depends on flawless execution to justify the forward multiple, while the bear case is a real risk given the high short interest and recent loss of analyst support. The stance would upgrade to bullish on confirmation of sustained net profitability and a reversal in analyst sentiment. It would turn bearish on a material earnings miss or guidance cut.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Clearwater Analytics's 12-month outlook, with a consensus price target around $31.93 and implied upside of +30.0% versus the current price.
Average Target
$31.93
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$20 - $32
Analyst target range
Analyst coverage for CWAN appears limited, with only two analysts providing estimates for future EPS and revenue, and no consensus price target data provided in the dataset. The average revenue estimate for the next period is $1.54 billion, with a range from $1.52B to $1.56B. The average EPS estimate is $1.21. The lack of a published consensus target price and the low analyst count suggest this is a stock with limited institutional research coverage, which can lead to higher volatility and less efficient price discovery. The recent pattern of institutional ratings reveals a decidedly bearish shift in sentiment. In the first two months of 2026, multiple firms including Morgan Stanley, UBS, Wells Fargo, Piper Sandler, Loop Capital, and Oppenheimer downgraded the stock from 'Buy' or 'Outperform' ratings to 'Neutral', 'Equal-Weight', or 'Hold'. This unified downgrade activity, likely triggered by the Enfusion acquisition and integration concerns, signals a significant reduction in analyst conviction and creates a substantial overhang on the stock. The wide dispersion in historical valuation multiples further underscores the high uncertainty surrounding the company's future financial performance.
Bulls vs Bears: CWAN Investment Factors
The evidence for CWAN presents a classic growth-at-a-price tension. Bullish arguments are grounded in powerful top-line momentum (72% YoY revenue growth), a high-margin SaaS model, and strong internal cash generation. Bearish concerns focus on the recent collapse in analyst sentiment, current lack of profitability, and a valuation that remains demanding. Currently, the bear side holds stronger near-term evidence, as the unified analyst downgrades signal a material shift in the professional investment narrative. The single most important tension is between the company's explosive acquisition-fueled growth and its ability to successfully integrate these acquisitions to achieve sustained net profitability. The resolution of this integration risk will determine whether the stock re-rates higher on proven execution or faces further multiple compression.
Bullish
- Explosive Revenue Growth: Q4 2025 revenue surged 71.95% year-over-year to $217.46 million, driven by strategic acquisitions. This positions the company for significant scale as it integrates its expanded platform for the full investment lifecycle.
- Strong SaaS Gross Margins: The company maintains a robust gross margin of 67.24%, consistent with a high-margin SaaS business model. This provides a solid foundation for future profitability as operating expenses are scaled.
- Positive Free Cash Flow: CWAN generated $164.29 million in trailing twelve-month free cash flow. This is a critical strength for a growing but currently unprofitable company, providing internal funding for operations and reducing reliance on external capital.
- Low Market Beta: With a beta of 0.596, the stock is approximately 40% less volatile than the broader market. This defensive characteristic makes it a relatively stable holding within the technology sector, appealing to risk-averse investors.
Bearish
- Recent Wave of Analyst Downgrades: Multiple major firms (Morgan Stanley, UBS, Wells Fargo, etc.) downgraded CWAN to 'Neutral' or 'Hold' in early 2026. This unified loss of conviction, likely tied to acquisition integration risks, creates a significant sentiment overhang.
- Current Net Losses and Margin Pressure: The company reported a Q4 2025 net loss of -$11.76 million, with a net margin of -5.41%. The operating margin also declined to 4.95%, indicating profitability remains elusive and integration costs may be pressuring margins.
- Elevated Valuation on Sales Basis: The trailing Price-to-Sales ratio of 8.95x is elevated, especially for a company not yet profitable. While down from historical extremes, this multiple demands flawless execution and sustained high growth to justify.
- High Short Interest: A short ratio of 7.23 indicates substantial bearish sentiment among traders. While this can fuel a short squeeze, it also reflects deep-seated skepticism about the company's near-term prospects and valuation.
CWAN Technical Analysis
The stock is in a sustained but volatile uptrend, having gained 9.89% over the past year and currently trading at its 52-week high of $24.56, representing 100% of its 52-week range. This positioning at the high suggests strong bullish momentum but also raises concerns about potential overextension and vulnerability to a pullback. Recent momentum shows a positive but modest 0.99% gain over the past month, which is notably weaker than the 4.60% gain over the last three months, indicating a significant deceleration in the rate of ascent and a possible consolidation phase. The stock exhibits low systematic risk with a beta of 0.596, meaning it is approximately 40% less volatile than the broader market, which is a key consideration for risk-averse investors in the technology sector. Short-term momentum is positive but has diverged from the market, with a 1-month gain of 0.99% compared to the SPY's loss of -2.86%, resulting in a strong 1-month relative strength of 3.85. However, the 3-month relative strength of -10.37 indicates the stock has significantly underperformed the SPY's 14.97% gain over that period, highlighting a recent period of relative weakness despite its absolute price gains. The stock has experienced a maximum drawdown of -35.8% during the provided period, underscoring its potential for significant volatility despite its low beta. Key technical support is at the 52-week low of $15.74, while immediate resistance is at the current 52-week high of $24.56. A decisive breakout above $24.56 could signal a continuation of the uptrend, while a failure to hold recent gains could see a test of lower support levels. The stock's low beta of 0.596 suggests it is a defensive holding within the tech sector, but the high short ratio of 7.23 indicates a substantial bearish sentiment among some traders, which could fuel a sharp rally on positive news (a short squeeze).
Beta
0.60
0.60x market volatility
Max Drawdown
-35.8%
Largest decline past year
52-Week Range
$16-$25
Price range past year
Annual Return
+9.9%
Cumulative gain past year
| Period | CWAN Return | S&P 500 |
|---|---|---|
| 1m | +1.0% | -3.6% |
| 3m | +4.6% | +15.3% |
| 6m | +1.8% | +6.1% |
| 1y | +9.9% | +18.6% |
| ytd | +1.9% | +6.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CWAN Fundamental Analysis
Revenue growth has been exceptionally strong, with Q4 2025 revenue of $217.46 million representing a year-over-year growth of 71.95%. This explosive growth is likely driven by acquisitions, as evidenced by the substantial increase from $126.47 million in Q4 2024. However, the sequential trend from Q3 2025 ($205.11 million) shows a more normalized quarterly increase, suggesting the massive YoY jump is acquisition-fueled and raises questions about organic growth sustainability. Gross margins remain healthy at 67.24% for the latest quarter, consistent with a high-margin SaaS business model. The company is currently unprofitable on a net income basis, reporting a Q4 2025 net loss of -$11.76 million, translating to a net margin of -5.41%. This represents a significant deterioration from the Q4 2024 net income of $419.28 million, which was heavily skewed by a large income tax benefit. The operating margin for Q4 2025 was a slim 4.95%, down from 6.34% in Q3 2024, indicating potential margin pressure from integration costs or investments. The gross margin of 67.24% is robust for the software industry, but the path to sustained net profitability remains a key focus. The balance sheet shows moderate leverage with a debt-to-equity ratio of 0.44, and a strong current ratio of 1.83 indicates good short-term liquidity. The company generated positive free cash flow of $164.29 million on a trailing twelve-month basis, which is a critical positive for a growing but unprofitable company, as it provides internal funding for operations and growth. Return on equity is negative at -1.92%, and return on assets is -0.08%, reflecting the current period of net losses and significant asset base expansion, likely from acquisitions.
Quarterly Revenue
$217457000.0B
2025-12
Revenue YoY Growth
+71.95%
YoY Comparison
Gross Margin
67.24%
Latest Quarter
Free Cash Flow
$164287000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CWAN Overvalued?
Given the negative trailing net income and EPS of -$0.0059, the primary valuation metric selected is the Price-to-Sales (PS) ratio, as the P/E ratio is not meaningful. The trailing PS ratio is elevated at 8.95x. The forward-looking valuation is more informative, with an estimated forward P/E of 28.03x based on analyst EPS estimates of $1.21, indicating the market is pricing in a significant return to profitability. Compared to industry averages, data is not available in the provided dataset for a direct peer comparison of PS or forward P/E multiples. Therefore, a peer-based premium/discount assessment cannot be quantified. The valuation must be assessed based on the company's own historical context and growth profile. Historically, the current PS ratio of 8.95x sits well below the extreme highs seen in 2021-2022 (e.g., 77.12x in Q1 2021) but is above levels seen in late 2023 and early 2024 (e.g., 27.97x in Q2 2023). The forward P/E of 28.03x suggests the market is anticipating substantial earnings growth. The stock's valuation reflects a transition phase, moving from a hyper-growth, acquisition-fueled story with extreme sales multiples towards a more normalized growth-and-profitability model, as implied by the forward earnings multiple.
PE
-172.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -5199x~10108x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
90.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is the company's current lack of profitability, with a Q4 2025 net margin of -5.41% and negative ROE of -1.92%. While revenue grew 72% YoY, this was acquisition-driven, raising sustainability questions for organic growth. The operating margin of 4.95% is thin and has declined from prior quarters, indicating potential pressure from integration costs. Although free cash flow is positive at $164M TTM and the debt-to-equity ratio of 0.44 is moderate, the company remains dependent on continued growth to justify its elevated PS ratio of 8.95x.
Market & Competitive Risks: The key market risk is valuation compression. The stock trades at a forward P/E of 28x based on anticipated but not yet realized profits. A failure to meet these earnings expectations could trigger significant multiple contraction. The stock's low beta of 0.596 offers some defensive quality but does not shield it from company-specific disappointments. Competitive risks are heightened as the company expands from its core back-office accounting into front and middle-office capabilities via acquisitions, entering more contested market segments.
Worst-Case Scenario: The worst-case scenario involves a botched integration of recent acquisitions (like Enfusion), leading to customer attrition, soaring operational costs, and a material miss on the $1.21 forward EPS estimate. This could trigger another round of analyst downgrades, a loss of investor confidence, and a rush for the exits exacerbated by the high short interest. Realistic downside could see the stock retesting its 52-week low of $15.74, which from the current price of $24.56 represents a potential loss of approximately -36%. The historical maximum drawdown of -35.8% provides a precedent for this magnitude of decline.
FAQ
The key risks are, in order of severity: 1) Execution/Integration Risk: Failure to successfully integrate recent acquisitions like Enfusion could destroy value (evidenced by analyst downgrades). 2) Profitability Risk: The company is currently unprofitable (net margin -5.41%), and a delay in achieving the $1.21 EPS estimate could crush the stock. 3) Sentiment Risk: High short interest (short ratio 7.23) and limited analyst coverage can amplify volatility. 4) Valuation Risk: An elevated PS ratio of 8.95x leaves the stock vulnerable to multiple compression if growth decelerates.
The 12-month forecast presents three scenarios. The Base Case (55% probability) sees the stock trading between $22 and $26 as the company meets revenue targets but struggles with margins. The Bull Case (25% probability) could drive the stock to $28-$32 on successful integration and earnings beats. The Bear Case (20% probability) risks a fall to the $15.74-$20 range on integration failures and missed estimates. The Base Case is most likely, implying a relatively flat to slightly positive return from the current $24.56, with high uncertainty.
CWAN's valuation is demanding and appears fairly valued to slightly overvalued based on current fundamentals. The trailing Price-to-Sales ratio of 8.95x is elevated for a company not yet profitable. However, the forward P/E of 28.03x, based on an estimated $1.21 EPS, suggests the market is paying for future earnings growth that has not materialized. The valuation implies the market expects successful integration and a rapid transition to profitability. Any stumble could make the stock look overvalued quickly.
CWAN is not a clear-cut buy at current levels. While it has compelling attributes like 72% revenue growth and strong free cash flow, it is currently rated Hold due to significant integration risks and a recent wave of analyst downgrades. For aggressive growth investors comfortable with high uncertainty, any dip toward the lower end of its range ($20-$22) might present a more favorable risk/reward entry. Conservative investors should wait for concrete evidence of sustained profitability before considering a position.
CWAN is unsuitable for short-term trading due to its low beta (0.596) limiting explosive moves and the high uncertainty around near-term catalysts. It is better suited for a long-term investment horizon of 3-5 years, allowing time for the integration story to play out and for the company to potentially achieve its profitability targets. The stock's low market correlation offers diversification benefits for a long-term portfolio, but investors must be prepared for significant company-specific volatility, as shown by its -35.8% max drawdown.